Fexofenadine (Allegra) Dosing with CrCl 35 mL/min
For an adult with a creatinine clearance of 35 mL/min, reduce fexofenadine to 60 mg once daily. 1
Rationale for Dose Reduction
The FDA drug label explicitly states that consumers with kidney disease should "ask a doctor" before using standard doses 1. With a CrCl of 35 mL/min, this patient has moderate renal impairment (Stage 3b CKD), which necessitates dose adjustment.
Standard dosing in normal renal function:
- 60 mg twice daily (12-hour formulation) OR
- 180 mg once daily (24-hour formulation) 1
Adjusted dosing for CrCl 35 mL/min:
- 60 mg once daily (half the total daily dose)
Key Clinical Considerations
Why This Dose Adjustment Matters
Fexofenadine is primarily renally eliminated, and reduced kidney function leads to drug accumulation 2. While fexofenadine has an excellent safety profile with minimal sedation even at high doses 2, appropriate dose reduction in renal impairment remains important to:
- Minimize unnecessary drug exposure
- Maintain the favorable safety profile
- Prevent potential accumulation-related adverse effects
Practical Implementation
- Use the 60 mg tablet formulation once daily rather than the 180 mg tablet
- Take with water, can be taken without regard to meals
- Do not exceed 60 mg in 24 hours for this patient
- No additional dose adjustment needed for elderly patients beyond the renal adjustment 1
Common Pitfall to Avoid
Do not use the 24-hour 180 mg formulation in patients with moderate renal impairment. The 12-hour 60 mg tablet given once daily provides appropriate dosing and allows for easier titration if needed.
Monitoring
While fexofenadine is well-tolerated even in renal impairment 2, monitor for:
- Efficacy of symptom control (may need clinical reassessment if 60 mg once daily is insufficient)
- Any unusual adverse effects, though these remain rare